The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 302 participants.

Also called NCT05719376

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 302 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05719376
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05719376. Randomized; no masking; primary purpose treatment. Start 2023-02 (anticipated); primary completion 2026-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes
Condition
Kidney Failure, Chronic
Intervention (Drug)
Monofer (experimental)
Intervention (Drug)
control group
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct05719376
Content hash
e4cc9c4b1449c989439a668f4c87fd5a67ad685b629aafc54868dfebfb24385a